Cargando…
Gilteritinib (XOSPATA®) in Turkey: Early Access Program Results
BACKGROUND AND OBJECTIVES: Gilteritinib (XOSPATA®, Astellas) is a type I oral FLT3 inhibitor, a tyrosine kinase AXL inhibitor, involved in both c-Kit and FMS-like tyrosine kinase 3 (FLT3) resistance. In the phase 3 ADMIRAL trial, gilteritinib was compared with the standard of care in (R/R) acute mye...
Autores principales: | Dogu, Mehmet Hilmi, Tekgunduz, Ali Irfan Emre, Deveci, Burak, Korkmaz, Gulten, Comert, Melda, Sevindik, Omur Gokmen, Yokus, Osman, Serin, Istemi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171205/ https://www.ncbi.nlm.nih.gov/pubmed/37180209 http://dx.doi.org/10.4084/MJHID.2023.031 |
Ejemplares similares
-
PB1897: GILTERITINIB IN TURKEY: EARLY ACCESS PROGRAM RESULTS
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2023) -
Acute Lymphoblastic Leukemia in Routine Practice: A Turkish Multicenter Study
por: Çiftçiler, Rafiye, et al.
Publicado: (2019) -
First-line Usage of Daratumumab, Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome (CD-POEMS)
por: Sevindik, Omur Gokmen, et al.
Publicado: (2022) -
The use of hypomethylating agents in hematologic malignancies: treatment preferences and results
por: Serin, Istemi, et al.
Publicado: (2021) -
Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
por: Serin, Istemi, et al.
Publicado: (2020)